Tyra Biosciences Q3 net loss widens on higher R&D costs
TYRA•Tyra Biosciences reported a third-quarter net loss of $51.12 million as research and development costs rose, mainly due to dabogratinib clinical trials. It completed a $400 million financing and expects its cash resources to fund operations through 2030.
1. Quarterly results
Tyra Biosciences’ third-quarter net loss was $51.12 million, while operating expenses were $54.89 million. Higher research and development spending, driven mainly by dabogratinib development activities in ongoing clinical trials, contributed to the loss widening year over year. Personnel and facility costs also increased.
2. Cash and plans
The company completed a $400 million financing and expects its current cash resources to fund operations through 2030. Pending regulatory feedback, it plans to initiate a Phase 3 adjuvant study for IR NMIBC in 2027 and expects additional clinical results for its LG-UTUC and ACH programs that year.
